Organon & Co. (NYSE:OGN – Get Free Report) has been given a consensus recommendation of “Reduce” by the seven brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating and five have given a hold rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.40.
Several equities research analysts recently commented on OGN shares. BNP Paribas Exane reiterated a “neutral” rating and set a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Weiss Ratings cut Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. Finally, Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and increased their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th.
Get Our Latest Stock Report on OGN
Organon & Co. Stock Down 0.0%
Organon & Co. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is 10.39%.
Institutional Trading of Organon & Co.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Private Management Group Inc. grew its position in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after buying an additional 1,204,979 shares in the last quarter. California State Teachers Retirement System raised its holdings in Organon & Co. by 34.8% in the first quarter. California State Teachers Retirement System now owns 327,075 shares of the company’s stock valued at $1,959,000 after acquiring an additional 84,497 shares in the last quarter. UBS Group AG raised its holdings in Organon & Co. by 55.2% in the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. Vanguard Group Inc. raised its holdings in Organon & Co. by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after acquiring an additional 987,979 shares in the last quarter. Finally, Orographic Financial Advisors LLC bought a new position in Organon & Co. during the 1st quarter valued at $1,522,000. 77.43% of the stock is owned by hedge funds and other institutional investors.
Organon & Co. Company Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Featured Articles
- Five stocks we like better than Organon & Co.
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
- Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead
- Walmart and Home Depot Earnings Show the K (Shaped Economy) Is Here to Stay
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
